azasetron

a selective 5-HT3 receptor antagonist; structure given in first source;

Also Known As:

N-(1-azabicyclo(2.2.2)oct-3-yl)-6-chloro-4-methyl-3-oxo-3,4 -dihydro-2H-1,4-benzoxazine-8-carboxamide hydrochloride; Y 25130; Y-25130; azasetron, (+-)-isomer; 2H-1,4-Benzoxazine-8-carboxamide, N-1-azabicyclo(2.2.2)oct-3-yl-6-chloro-3,4-dihydro-4-methyl-3-oxo-, monohydrochloride

Networked: 36 relevant articles (5 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Oxazines: 9
    - azasetron: 36
- Bridged-Ring Heterocyclic Compounds
  - Heterocyclic Bridged Bicyclo Compounds
    - azasetron: 36

Experts

1.	Nasehi, Mohammad: 3 articles (09/2017 - 03/2014)
2.	Zarrindast, Mohammad-Reza: 3 articles (09/2017 - 03/2014)
3.	Wei, Feng: 2 articles (01/2020 - 10/2012)
4.	Endo, Junki: 2 articles (01/2017 - 09/2012)
5.	Funaguchi, Norihiko: 2 articles (01/2017 - 09/2012)
6.	Iihara, Hirotoshi: 2 articles (01/2017 - 09/2012)
7.	Ito, Fumitaka: 2 articles (01/2017 - 09/2012)
8.	Itoh, Yoshinori: 2 articles (01/2017 - 09/2012)
9.	Minatoguchi, Shinya: 2 articles (01/2017 - 09/2012)
10.	Ohno, Yasushi: 2 articles (01/2017 - 09/2012)

Related Diseases

1.	Vomiting 11/01/1993 - "The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesis." 04/24/1991 - "Y-25130, at the dose of 0.3 mg/kg i.v., almost completely inhibited X-radiation-induced emesis in ferrets. " 05/01/1997 - "[Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP]." 11/01/1993 - "Y-25130 (0.1-1.0 mg/kg) dose-dependently prolonged the latency to the first vomiting and decreased the number of vomitings induced by cisplatin in dogs. " 04/24/1991 - "The i.v. dose of 0.3 mg/kg of Y-25130 was enough to almost completely inhibit cisplatin-induced emesis in dogs for 24 h. "
2.	Nausea 05/01/1997 - "[Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP]." 05/01/2006 - "However, the grade of nausea was significantly lower in the ramosetron group than in the azasetron group. " 03/01/1996 - "From these data, continuous intravenous infusion of azasetron was considered to be highly effective in prophylaxis of nausea and vomiting induced by anticancer drugs." 03/01/1996 - "[Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP]." 12/01/2012 - "These findings indicated that the developed patch for azasetron is promising for the treatment of delayed chemotherapy-induced nausea and vomiting, and the in vitro skin permeation experiments could be useful to predict the in vivo performance of transdermal azasetron patches."
3.	Ovarian Neoplasms (Ovarian Cancer) 02/15/2017 - "For triple combination therapy, azasetron, dexamethasone (reduced dose: 40% of 20 mg), and aprepitant (125 mg) were administered on Day 1, followed by only aprepitant (80 mg) administration on Days 2 and Day 3. RESULTS In 37 women with ovarian cancer, three symptoms, nausea, appetite loss, and dietary intake, were significantly improved by primarily adding aprepitant to double combination therapy in the delayed phase of MEC. "
4.	Postoperative Nausea and Vomiting (PONV) 01/01/2010 - "Comparison of azasetron and ondansetron for preventing postoperative nausea and vomiting in patients undergoing gynecological laparoscopic surgery." 01/01/2021 - "This prospective trial aimed to explore whether dexmedetomidine (DEX) combined with azasetron (AZA) can further drop the incidence of PONV in patients undergoing ambulatory thyroidectomy compared with AZA. " 01/01/2021 - "Conclusions: Intraoperative dexmedetomidine combined with azasetron failed to drop the incidence of 24-h PONV compared with azasetron alone in patients undergoing ambulatory thyroidectomy." 01/01/2010 - "In conclusion, azasetron (10 mg) produced same incidence of PONV as ondansetron (8 mg) in patients undergoing general anesthesia for gynecological laparoscopic surgery. " 01/01/2010 - "We compared the prophylactic effects of intravenously administered azasetron (10 mg) and ondansetron (8 mg) on postoperative nausea and vomiting (PONV) in patients undergoing gynecological laparoscopic surgery under general anesthesia. "
5.	Lung Neoplasms (Lung Cancer) 05/01/2006 - "[Comparison of ramosetron and azasetron for prevention of acute and delayed cisplatin-induced emesis in lung cancer patients]." 05/01/2006 - "We performed a retrospective study that compared the efficacy and safety of ramosetron with azasetron in a case of acute and delayed emesis induced by cisplatin (CDDP)-included chemotherapy in patients with lung cancer. " 09/01/2012 - "A randomized non-inferiority study comparing acute antiemetic effects between oral azasetron and intravenous granisetron was performed in 105 patients receiving the first course of carboplatin-based chemotherapy for lung cancer. "

Related Drugs and Biologics

1.	5-HT3 Serotonin Receptors (5 HT3 Receptor)
2.	Dexamethasone (Maxidex)
3.	Antiemetics
4.	Granisetron (Kytril)
5.	Cisplatin (Platino)
6.	Aprepitant (Emend)
7.	Ondansetron (Zofran)
8.	Carboplatin (JM8)
9.	Dexmedetomidine
10.	Serotonin (5 Hydroxytryptamine)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Intravenous Infusions
4.	Thyroidectomy
5.	Intravenous Injections